These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18218303)

  • 1. Darbepoetin-alfa in renal-transplant patients: an observational monocentric study.
    Ribes D; Kamar N; Guitard J; Esposito L; Rostaing L
    Clin Nephrol; 2008 Feb; 69(2):102-6. PubMed ID: 18218303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
    Kamar N; Guitard J; Ribes D; Esposito L; Rostaing L
    Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.
    Mann J; Kessler M; Villa G; Martinez-Castelao A; Feldt-Rasmussen B; Cruz J; Hörl WH; Mattin C; Praml C; Wilkie M
    Clin Nephrol; 2007 Mar; 67(3):140-8. PubMed ID: 17390738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
    Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
    Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW; Chang CH
    Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients.
    Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B
    Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure.
    André JL; Deschênes G; Boudailliez B; Broux F; Fischbach M; Gagnadoux MF; Horen B; Lahoche-Manucci A; Macher MA; Roussel B; Tsimaratos M; Loirat C
    Pediatr Nephrol; 2007 May; 22(5):708-14. PubMed ID: 17216497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study.
    Donck J; Gonzalez-Tabares L; Chanliau J; Martin H; Stamatelou K; Manamley N; Farouk M; Addison J
    Adv Ther; 2014 Nov; 31(11):1155-68. PubMed ID: 25367412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.
    Choi P; Farouk M; Manamley N; Addison J
    Adv Ther; 2013 Nov; 30(11):1007-17. PubMed ID: 24173670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD; Kolmakova E; Fung M; Malecki R; Vinhas J; Dellanna F; Thomas M; Manamley N; Ferenczi S
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH; Holzer H; Mayer GJ;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India.
    Mazahir R; Anand K; Pruthi PK
    Eur J Pediatr; 2023 Jan; 182(1):101-109. PubMed ID: 36220980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
    Galle JC; Claes K; Kiss I; Winearls CG; Herlitz H; Guerin A; Di Giulio S; Suranyi MG; Bridges I; Addison J; Farouk M
    Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.